Iterum Therapeutics (ITRM) Enterprise Value (2017 - 2022)
Historic Enterprise Value for Iterum Therapeutics (ITRM) over the last 6 years, with Q3 2022 value amounting to -$64.3 million.
- Iterum Therapeutics' Enterprise Value rose 2495.36% to -$64.3 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$64.3 million, marking a year-over-year increase of 2495.36%. This contributed to the annual value of -$81.3 million for FY2021, which is 45837.45% down from last year.
- Per Iterum Therapeutics' latest filing, its Enterprise Value stood at -$64.3 million for Q3 2022, which was up 2495.36% from -$68.9 million recorded in Q2 2022.
- Over the past 5 years, Iterum Therapeutics' Enterprise Value peaked at -$4.8 million during Q4 2019, and registered a low of -$135.3 million during Q2 2018.
- Moreover, its 5-year median value for Enterprise Value was -$69.2 million (2019), whereas its average is -$61.6 million.
- In the last 5 years, Iterum Therapeutics' Enterprise Value surged by 9428.63% in 2019 and then crashed by 89317.5% in 2021.
- Quarter analysis of 5 years shows Iterum Therapeutics' Enterprise Value stood at -$84.6 million in 2018, then surged by 94.29% to -$4.8 million in 2019, then tumbled by 201.55% to -$14.6 million in 2020, then crashed by 458.37% to -$81.3 million in 2021, then rose by 20.92% to -$64.3 million in 2022.
- Its Enterprise Value stands at -$64.3 million for Q3 2022, versus -$68.9 million for Q2 2022 and -$75.3 million for Q1 2022.